Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,708 across all filing types
Latest filing 2019-02-12 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a communication from the company to stock exchanges reporting the outcome of a Board Meeting held on February 12, 2019. It announces the approval of unaudited financial results for the quarter and nine months ended December 31, 2018, prepared under Indian Accounting Standards, along with the review report of statutory auditors. It also declares a second interim dividend with record and payment dates. Additionally, there is a press release summarizing the financial performance for the third quarter of FY 2018-19, including revenue and profit figures, and a dividend recommendation. The document contains actual financial results and dividend declaration details, which are substantive financial data. The length is 3423 characters, which is under 5000, but the content includes detailed financial results and dividend declaration, not just an announcement of report availability. Therefore, this is an Interim / Quarterly Report (IR) rather than a mere announcement or press release. The presence of unaudited financial results for a quarter and nine months period confirms it as an Interim / Quarterly Report. Q3 2019
2019-02-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding an updated earnings call for the quarter and nine months ended December 31, 2018. It announces the timing change of the earnings call and provides details for the conference call with management to discuss the financial results. The document does not contain actual financial statements or detailed financial analysis but is an announcement about the earnings call event. Therefore, it is not the earnings release itself but an announcement related to the earnings call. Given the document length is short (2617 characters) and it primarily serves to notify about the earnings call, the appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2019-02-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a letter from NATCO Pharma Limited to stock exchanges announcing an upcoming earnings call scheduled for February 13, 2019, to discuss the company's financial results for the quarter and nine months ended December 31, 2018. It includes details about the conference call logistics and contact information. The document does not contain actual financial results or substantive financial data but is an announcement of the earnings call event. Therefore, it is not the Earnings Release itself but an announcement related to the earnings call. Given the content and length (2384 characters), this fits best under the category of Call Transcript (CT) announcement or related. However, since it is an announcement of the earnings call and not the transcript, and no transcript text is included, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories precisely.
2019-02-05 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice informing the stock exchanges about an upcoming Board Meeting scheduled for February 12, 2019. The agenda includes consideration of unaudited financial results for the quarter and nine months ended December 31, 2018, and the possibility of declaring a second interim dividend. The document also mentions the closure of the trading window as per SEBI regulations. The document is short (1374 characters) and serves as an announcement of a meeting and potential financial results, not the results themselves or detailed financial data. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not contain actual financial statements or detailed report content.
2019-02-04 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a notice informing the stock exchanges about an upcoming Board Meeting scheduled for February 12, 2019. The agenda includes consideration of unaudited financial results for the quarter and nine months ended December 31, 2018, and the possibility of declaring a second interim dividend. The document also mentions the closure of the trading window as per SEBI regulations. The document is short (1374 characters) and serves as an announcement of a meeting rather than containing any financial data or results itself. Therefore, it is not an Interim Report or Earnings Release but a Regulatory Filing notifying about the Board Meeting and related compliance matters.
2019-02-02 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing of an Abbreviated New Drug Application (ANDA) with the U.S. FDA for a generic drug. It is addressed to stock exchanges and is intended for public information. The document is short (2324 characters) and does not contain any financial statements, detailed financial analysis, or regulatory certifications. It is clearly a corporate announcement about a product development and regulatory filing, not a financial report or detailed regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2019-01-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.